Downloads

  1. Autoimmune Drugs For Women: What To Bring To The Clinic 9/24/2026

    Autoimmune disease is one of the most sex-skewed categories in medicine. Sex, reproductive status, and hormonal state should not be treated as background noise. 

  2. Unlocking Challenging Targets With Macrocycle DNA-Encoded Libraries 9/22/2026

    Discover how macrocycle DNA-encoded libraries can uncover new opportunities for challenging targets and help researchers translate promising screening hits into starting points for drug discovery.

  3. Can An Ibogaine Analog Preserve The Therapeutic Potential Without The Trip Or Cardiac Risk? 9/17/2026

    Ibogaine’s anecdotal and clinical signals on cravings, withdrawal, and PTSD are growing, but the biggest obstacle is that ibogaine carries serious cardiac risk and hallucinations.

  4. Viewing Treatment Resistance As A Target 9/16/2026

    Viewing treatment resistance as a target instead of an undesirable side effect could allow effective treatments to work for longer.

  5. Wall Street Is Wary Of NAMs — And For Good Reason: What Happens To Yesterday's Drugs? 9/15/2026

    Part 2 follows the consequences into Wall Street, asking what better evidence could mean for pharmaceutical valuations and, ultimately, drugs already in the portfolio.

  6. Using Low-Intensity Focused Ultrasound To Open The Blood–Brain Barrier 9/11/2026

    We caught up with Davinder Ramsingh, MD, to talk about the potential of using low-intensity focused ultrasound (LIFU) to open the blood–brain barrier.

  7. Wall Street Is Wary Of NAMs — And For Good Reason: The Evidentiary Shift 9/10/2026

    Part I of this series focuses on the evidentiary shift of how NAMs may change the architecture of evidence and how that transition unfolds.

  8. Overcoming The Obstacles Of Spray-Dried Dispersion Scale-Up 9/9/2026

    SDD scale-up introduces scale-dependent risks that threaten bioavailability, stability, and manufacturability. This white paper details a model-based framework for managing those risks from early feasibility through commercial production.

  9. Measuring Cellular Water Content As A New Tool For Organoid Characterization 9/9/2026

    A collaboration between MIT, KAIST, and Dana Farber Cancer Institute created a technology that, for the first time, quantifies water content in single organoids.

  10. Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases 9/4/2026

    Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition.